Cepheid Pandemic Pushes Handheld qPCR Devices Closer to Commercialization Premium Miniaturized sample-to-answer devices in development hint at an evolving molecular diagnostics landscape but launch timelines for these platforms remain unclear. Demand for Cepheid SARS-CoV-2 Point-of-Care Tests Expected to Continue Through 2022 Premium The Danaher subsidiary's core revenues grew more than 90 percent in the first quarter of 2021 and it expects to ship 45 million SARS-CoV-2 tests for the year. Danaher Q1 Revenues Up 58 Percent The firm beat the consensus Wall Street estimate on the top line as its Life Sciences revenues grew 115 percent and its Diagnostics revenue rose 34 percent. Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent. FDA Posts Info on Impact of SARS-CoV-2 Mutations on Test Effectiveness The FDA identified molecular tests from Mesa Biotech, Applied DNA Sciences, Thermo Fisher Scientific, and Cepheid that could be affected by certain mutations. Feb 18, 2021 WHO Finds High Diagnostic Accuracy in Three Classes of MDx Technologies for TB Testing, Resistance Jan 28, 2021 Danaher Q4 Revenues up 39 Percent Dec 29, 2020 Cepheid Gets FDA Emergency Use Authorization for US Department of Defense Coronavirus Test Dec 1, 2020 Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization Nov 24, 2020 Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test Nov 17, 2020 Cepheid Developing New Target for BCR-ABL Test for Leukemia Patients Premium Oct 22, 2020 Danaher Q3 Revenues Up 35 Percent Oct 9, 2020 India Banks on Decentralized Molecular COVID-19 Testing Premium Sep 25, 2020 Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization Sep 8, 2020 As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza Premium Jul 31, 2020 SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency Premium Jul 23, 2020 Danaher Q2 Revenues Spike 19 Percent Jul 21, 2020 AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry Jul 17, 2020 Cepheid Debuts 10-Color Molecular Detection Technology With New Tuberculosis Test Premium May 14, 2020 New Study Finds Abbott's ID Now SARS-CoV-2 Test Misses Sensitivity Mark May 7, 2020 Danaher Q1 Revenues Up 3 Percent; Joyce Retiring as CEO Apr 15, 2020 CMS Increases Payment Rates for High-Throughput SARS-CoV-2 Tests Apr 1, 2020 Despite Potential, Experts Debate Whether Decentralized MDx for Coronavirus Can Flatten Curve Mar 21, 2020 Cepheid Coronavirus Assay First Point-of-Care Test to Get FDA Emergency Use Authorization Feb 28, 2020 Cepheid, Sherlock Biosciences Partner on SARS-CoV-2 Diagnostic Test Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.